We are live on ! Find out more
NVO

Novo Nordisk

580 hedge funds and large institutions have $9.18B invested in Novo Nordisk in 2019 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 171 increasing their positions, 204 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more call options, than puts

Call options by funds: $58.1M | Put options by funds: $23.1M

88% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 41

15% more capital invested

Capital invested by funds: $7.99B → $9.18B (+$1.19B)

5% more funds holding

Funds holding: 550580 (+30)

0.2% more ownership

Funds ownership: 18.15%18.35% (+0.2%)

16% less repeat investments, than reductions

Existing positions increased: 171 | Existing positions reduced: 204

17% less funds holding in top 10

Funds holding in top 10: 1210 (-2)

Holders
580
Holders Change
+30
Holders Change %
+5.45%
% of All Funds
12.55%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.22%
New
77
Increased
171
Reduced
204
Closed
41
Calls
$58.1M
Puts
$23.1M
Net Calls
+$35M
Net Calls Change
-$10.8M
Name Holding Trade Value Shares
Change
Change in
Stake
PNC Financial Services Group
51
PNC Financial Services Group
Pennsylvania
$25M -$236K -9,608 -1%
AIA
52
Avalon Investment & Advisory
Texas
$22.1M -$66.5K -2,706 -0.3%
Franklin Resources
53
Franklin Resources
California
$21.7M -$2.3M -93,426 -10%
SFM
54
Sphera Funds Management
Israel
$20.9M +$19.7M +800,000 New
CS
55
Credit Suisse
Switzerland
$20.7M +$9.49M +386,282 +96%
PFM
56
Parsec Financial Management
North Carolina
$20.4M +$358K +14,570 +2%
TL
57
Tirschwell & Loewy
New York
$19.7M -$189K -7,700 -1%
SI
58
Scout Investments
Missouri
$17.9M -$699K -28,458 -4%
Connor, Clark & Lunn Investment Management (CC&L)
59
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$17.7M +$9.9M +403,000 +147%
Two Sigma Investments
60
Two Sigma Investments
New York
$17.6M -$15.8M -641,750 -49%
O
61
OrbiMed
New York
$17.3M
Deutsche Bank
62
Deutsche Bank
Germany
$15.9M +$3.32M +135,206 +28%
US Bancorp
63
US Bancorp
Minnesota
$15.9M -$11.9K -484 -0.1%
Alyeska Investment Group
64
Alyeska Investment Group
Illinois
$15.7M +$14.7M +600,000 New
CIBC Asset Management
65
CIBC Asset Management
Ontario, Canada
$14.1M +$1.09M +44,216 +9%
Stifel Financial
66
Stifel Financial
Missouri
$13.5M +$825K +33,578 +7%
GHA
67
GW Henssler & Associates
Georgia
$13.4M +$572K +23,272 +5%
BTS
68
BB&T Securities
Virginia
$13.3M -$1.01M -41,016 -7%
BCPEM
69
Bain Capital Public Equity Management
Massachusetts
$13.2M +$12.4M +503,764 New
TCM
70
Tekla Capital Management
Massachusetts
$13.2M -$2.47M -100,600 -17%
HP
71
Hikari Power
Japan
$13M -$4.46M -181,500 -27%
Janus Henderson Group
72
Janus Henderson Group
United Kingdom
$13M +$1.25M +50,764 +11%
SI
73
Sofinnova Investments
California
$13M +$12.2M +495,468 New
NPA
74
Nichols & Pratt Advisers
Massachusetts
$12.9M +$308K +12,526 +3%
CTA
75
Carillon Tower Advisers
Florida
$12.2M -$624K -25,406 -5%

NVO Hedge Fund Activity: Q1 2019 in Review

580 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2019, worth a combined $9.18B — up 15% from $7.99B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new NVO positions and 41 closed out — a net gain of 36 holders — while 171 added to existing stakes and 204 trimmed.

The largest buyer was Amundi Asset Management US, opening a new position worth an estimated $46.1M. The largest seller was Alta Capital Management, cutting an estimated $41.5M.

  • 580 institutional investors held Novo Nordisk (NVO) as of Q1 2019, up from 550 in Q4 2018.
  • Funds reported $9.18B of Novo Nordisk stock for Q1 2019, up 15% quarter-over-quarter.
  • 77 funds opened new Novo Nordisk positions in Q1 2019 and 41 closed out, a net change of +36 holders.
  • The largest Novo Nordisk buyer in Q1 2019 was Amundi Asset Management US, an estimated $46.1M added.
  • The largest Novo Nordisk seller in Q1 2019 was Alta Capital Management, an estimated $41.5M sold.

Based on aggregated 13F filings for Q1 2019.